Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

E.D. Tex.

Seagen Inc. v. Daiichi Sankyo Co., Ltd., No. 2:20-cv-00337 (E.D. Tex. Sept. 14, 2021)

Claims Construed
Claim Construction
Court
U.S. District Court for the Eastern District of Texas, Marshall Division
Case No.
No. 2:20-cv-00337, Dkt. No. 155
Decided
September 14, 2021
Judge
Rodney Gilstrap, J.
Document
Memorandum Opinion and Order
Length
42 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court is the opening claim construction brief of Plaintiff Seagen Inc. (“Plaintiff”) (Dkt. No. 121), the response of Defendant Daiichi Sankyo Co., Ltd. and Intervenor- Defendants AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd. ( collectively, the “Defendants”) (Dkt. No. 130, filed on July 30, 2021), and the reply of Plaintiff (Dkt. No. 135, filed on August 6, 2021). The Court held a claim construction hearing on August 27, 2021 (see Dkt. No. 149).

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error

Other documents in this case